By Mill Chart
Last update: Mar 18, 2024
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) has caught the eye of our stock screener as an affordable growth stock. NASDAQ:BMRN is displaying robust growth metrics and also excels in terms of profitability, solvency, and liquidity. Additionally, it appears to be reasonably priced. Let's delve into the details.
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:BMRN scores a 7 out of 10:
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NASDAQ:BMRN has earned a 6 for valuation:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:BMRN has earned a 5 out of 10:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:BMRN was assigned a score of 7 for profitability:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
Check the latest full fundamental report of BMRN for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (4/24/2024, 7:00:01 PM)
After market: 87.99 -3.21 (-3.52%)91.2
-0.86 (-0.93%)
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biomarin Pharmaceutical (NASDAQ:BMRN) just reported results for the first quart...
First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and...
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host...
Investors seeking growth at a reasonable cost should explore BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO®...
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial...
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in...
The US Department of Justice has reportedly issued a subpoena to BioMarin Pharmaceutical (BRMN) seeking information related to sponsored testing programs for it